iifl-logo-icon 1

J B Chemicals & Pharmaceuticals Ltd Share Price

1,801.75
(-0.31%)
Jul 19, 2024|09:44:59 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open1,813.8
  • Day's High1,813.8
  • 52 Wk High1,940
  • Prev. Close1,807.35
  • Day's Low1,799.2
  • 52 Wk Low1,183.8
  • Turnover (lac)99.25
  • P/E51.56
  • Face Value1
  • Book Value192.37
  • EPS35.01
  • Mkt. Cap (Cr.)27,965.51
  • Div. Yield0.34
No Records Found

J B Chemicals & Pharmaceuticals Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

1,813.8

Prev. Close

1,807.35

Turnover(Lac.)

99.25

Day's High

1,813.8

Day's Low

1,799.2

52 Week's High

1,940

52 Week's Low

1,183.8

Book Value

192.37

Face Value

1

Mkt Cap (₹ Cr.)

27,965.51

P/E

51.56

EPS

35.01

Divi. Yield

0.34

J B Chemicals & Pharmaceuticals Ltd Corporate Action

6 Feb 2024

12:00 AM

Dividend

Dividend Amount: 5.5

Record Date: 16 Feb, 2024

arrow

24 May 2023

12:00 AM

Split

arrow

30 Jun 2023

12:00 AM

AGM

Announcement Date: 30 Jun, 2023

arrow

28 Jul 2023

12:00 AM

BookCloser

arrow

10 May 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

J B Chemicals & Pharmaceuticals Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

J B Chemicals & Pharmaceuticals Ltd SHAREHOLDING SNAPSHOT

21 Jul, 2024|02:03 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 53.78%

Foreign: 53.78%

Indian: 0.00%

Non-Promoter- 29.44%

Institutions: 29.44%

Non-Institutions: 16.77%

Custodian: 0.00%

Share Price

J B Chemicals & Pharmaceuticals Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2023Mar-2022Mar-2021Mar-2020

Equity Capital

15.51

15.46

15.46

15.46

Preference Capital

0

0

0

0

Reserves

2,426.98

2,088.21

1,791

1,429.83

Net Worth

2,442.49

2,103.67

1,806.46

1,445.29

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

2,189.87

1,891.99

1,640.74

1,250.13

yoy growth (%)

15.74

15.31

31.24

6.42

Raw materials

-743.69

-625.75

-569.13

-479.67

As % of sales

33.96

33.07

34.68

38.36

Employee costs

-399.06

-305.97

-293.78

-217.3

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

471.29

593.7

349.56

179.04

Depreciation

-71.28

-67.35

-65.09

-55.94

Tax paid

-110.29

-146.62

-71.41

-51.04

Working capital

298.14

110.36

28.72

67.62

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2018

Growth matrix (%)

Revenue growth

15.74

15.31

31.24

6.42

Op profit growth

-7.84

49.09

85.51

-10.11

EBIT growth

-20.74

70.46

93.19

-17.73

Net profit growth

-19.25

66.73

109.48

-25.99

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

3,484.18

3,149.28

2,424.24

2,042.52

1,774.73

Excise Duty

0

0

0

0

0

Net Sales

3,484.18

3,149.28

2,424.24

2,042.52

1,774.73

Other Operating Income

0

0

0

0

0

Other Income

37.27

9.94

39.23

112.38

50.67

J B Chemicals & Pharmaceuticals Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,594.25

125.293,82,370.02867.60.855,536.9998.75

Divis Laboratories Ltd

DIVISLAB

4,584.8

77.221,21,645.675310.652,259507.93

Cipla Ltd

CIPLA

1,506.65

32.741,21,616.251,038.40.563,444.92346.41

Zydus Lifesciences Ltd

ZYDUSLIFE

1,185.65

34.71,19,268.911,405.20.253,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,667.5

25.951,11,193.661,034.80.65,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT J B Chemicals & Pharmaceuticals Ltd

Management

Register Office

Registrar Office

Non-Exec. & Independent Dir.

Padmini Khare Kaicker

Non-Exec. & Independent Dir.

Sumit Bose

Chairman & Independent Directo

Ranjit Shahani.

Non-Exec & Non-Independent Dir

Prashant Kumar.

Whole Time Director & CEO

Nikhil Chopra

Non-Exec & Non-Independent Dir

GAURAV TREHAN

Company Sec. & Compli. Officer

SANDEEP PHADNIS

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Reports by J B Chemicals & Pharmaceuticals Ltd

Summary

J B Chemicals & Pharmaceuticals (JBC) was originally promoted and incorporated in Maharashtra by J B Mody as J B Mody Chemicals & Pharmaceuticals in December 18th, 1976. The Company is engaged in the business of manufacturing and marketing of diverse range of pharmaceuticals formulations, herbal remedies and APIs. The company has manufacturing units at Thane, Belapur, Ankleshwar, Panoli and Daman. The bulk drug plant at Panoli and formulation plant at Daman became operational in Apr.95. Products like metrogyl, rantac (a ranitidine-based formulation), and nicardia (a cardiac care medicine) form a significant part of the companys sales. JBC has its subsidiaries namely Lekar Healthcare Ltd and J.B Life Science Overseas Ltd. JBC had a tie-up with Justesa Imagen, Spain, to manufacture and market radio diagnostics under the Trazograf brand name. JBC has also diversified into high-growth agro-based products by acquiring McDa Agro (MAL). The products manufactured by MAL complement fertilisers and increase crop productivity. It has entered into a MoU with GNFC to distribute these products locally. The pharmaceutical divisions of Ifiunik Pharmaceuticals and Unique Pharmaceutical Laboratories has been merged into the company with effect from April 2000.Unique Chemicals (A Division of the company) manufacturing and marketing Bulk Drugs has been awarded Certificate of Suitability to Europeon Pharmacopoeia Monograph for Nifedipine EP from Europeon Directorate for the Quality Medicines.In F
Read More

Company FAQs

What is the J B Chemicals & Pharmaceuticals Ltd share price today?

Down Arrow

The J B Chemicals & Pharmaceuticals Ltd shares price on N/A is Rs.₹1800.8 today.

What is the Market Cap of J B Chemicals & Pharmaceuticals Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of J B Chemicals & Pharmaceuticals Ltd is ₹27950.77 Cr. as of 19 Jul ‘24

What is the PE and PB ratio of J B Chemicals & Pharmaceuticals Ltd?

Down Arrow

The PE and PB ratios of J B Chemicals & Pharmaceuticals Ltd is 51.56 and 9.71 as of 19 Jul ‘24

What is the 52 Week High and Low of J B Chemicals & Pharmaceuticals Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a J B Chemicals & Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of J B Chemicals & Pharmaceuticals Ltd is ₹1185 and ₹1935 as of 19 Jul ‘24

What is the CAGR of J B Chemicals & Pharmaceuticals Ltd?

Down Arrow

J B Chemicals & Pharmaceuticals Ltd's CAGR for 5 Years at 57.76%, 3 Years at 23.85%, 1 Year at 44.02%, 6 Month at 13.64%, 3 Month at 0.57% and 1 Month at 0.29%.

What is the shareholding pattern of J B Chemicals & Pharmaceuticals Ltd?

Down Arrow

The shareholding pattern of J B Chemicals & Pharmaceuticals Ltd is as follows:
Promoters - 53.78 %
Institutions - 29.44 %
Public - 16.78 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.